Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.


The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page


My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2008 1
2010 1
2013 1
2014 1
2015 1
2016 3
2017 3
2018 2
2019 6
2020 3
2021 5
2022 3
2023 4
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

30 results

Results by year

Filters applied: . Clear all
Page 1
Chromatin profiles classify castration-resistant prostate cancers suggesting therapeutic targets.
Tang F, Xu D, Wang S, Wong CK, Martinez-Fundichely A, Lee CJ, Cohen S, Park J, Hill CE, Eng K, Bareja R, Han T, Liu EM, Palladino A, Di W, Gao D, Abida W, Beg S, Puca L, Meneses M, de Stanchina E, Berger MF, Gopalan A, Dow LE, Mosquera JM, Beltran H, Sternberg CN, Chi P, Scher HI, Sboner A, Chen Y, Khurana E. Tang F, et al. Among authors: puca l. Science. 2022 May 27;376(6596):eabe1505. doi: 10.1126/science.abe1505. Epub 2022 May 27. Science. 2022. PMID: 35617398 Free PMC article.
Divergent clonal evolution of castration-resistant neuroendocrine prostate cancer.
Beltran H, Prandi D, Mosquera JM, Benelli M, Puca L, Cyrta J, Marotz C, Giannopoulou E, Chakravarthi BV, Varambally S, Tomlins SA, Nanus DM, Tagawa ST, Van Allen EM, Elemento O, Sboner A, Garraway LA, Rubin MA, Demichelis F. Beltran H, et al. Among authors: puca l. Nat Med. 2016 Mar;22(3):298-305. doi: 10.1038/nm.4045. Epub 2016 Feb 8. Nat Med. 2016. PMID: 26855148 Free PMC article.
Delta-like protein 3 expression and therapeutic targeting in neuroendocrine prostate cancer.
Puca L, Gavyert K, Sailer V, Conteduca V, Dardenne E, Sigouros M, Isse K, Kearney M, Vosoughi A, Fernandez L, Pan H, Motanagh S, Hess J, Donoghue AJ, Sboner A, Wang Y, Dittamore R, Rickman D, Nanus DM, Tagawa ST, Elemento O, Mosquera JM, Saunders L, Beltran H. Puca L, et al. Sci Transl Med. 2019 Mar 20;11(484):eaav0891. doi: 10.1126/scitranslmed.aav0891. Sci Transl Med. 2019. PMID: 30894499 Free PMC article. Clinical Trial.
N-Myc Induces an EZH2-Mediated Transcriptional Program Driving Neuroendocrine Prostate Cancer.
Dardenne E, Beltran H, Benelli M, Gayvert K, Berger A, Puca L, Cyrta J, Sboner A, Noorzad Z, MacDonald T, Cheung C, Yuen KS, Gao D, Chen Y, Eilers M, Mosquera JM, Robinson BD, Elemento O, Rubin MA, Demichelis F, Rickman DS. Dardenne E, et al. Among authors: puca l. Cancer Cell. 2016 Oct 10;30(4):563-577. doi: 10.1016/j.ccell.2016.09.005. Cancer Cell. 2016. PMID: 27728805 Free PMC article.
Extracellular Matrix in Synthetic Hydrogel-Based Prostate Cancer Organoids Regulate Therapeutic Response to EZH2 and DRD2 Inhibitors.
Mosquera MJ, Kim S, Bareja R, Fang Z, Cai S, Pan H, Asad M, Martin ML, Sigouros M, Rowdo FM, Ackermann S, Capuano J, Bernheim J, Cheung C, Doane A, Brady N, Singh R, Rickman DS, Prabhu V, Allen JE, Puca L, Coskun AF, Rubin MA, Beltran H, Mosquera JM, Elemento O, Singh A. Mosquera MJ, et al. Among authors: puca l. Adv Mater. 2022 Jan;34(2):e2100096. doi: 10.1002/adma.202100096. Epub 2021 Nov 14. Adv Mater. 2022. PMID: 34676924 Free PMC article.
Personalized In Vitro and In Vivo Cancer Models to Guide Precision Medicine.
Pauli C, Hopkins BD, Prandi D, Shaw R, Fedrizzi T, Sboner A, Sailer V, Augello M, Puca L, Rosati R, McNary TJ, Churakova Y, Cheung C, Triscott J, Pisapia D, Rao R, Mosquera JM, Robinson B, Faltas BM, Emerling BE, Gadi VK, Bernard B, Elemento O, Beltran H, Demichelis F, Kemp CJ, Grandori C, Cantley LC, Rubin MA. Pauli C, et al. Among authors: puca l. Cancer Discov. 2017 May;7(5):462-477. doi: 10.1158/2159-8290.CD-16-1154. Epub 2017 Mar 22. Cancer Discov. 2017. PMID: 28331002 Free PMC article.
Emerging Variants of Castration-Resistant Prostate Cancer.
Vlachostergios PJ, Puca L, Beltran H. Vlachostergios PJ, et al. Among authors: puca l. Curr Oncol Rep. 2017 May;19(5):32. doi: 10.1007/s11912-017-0593-6. Curr Oncol Rep. 2017. PMID: 28361223 Free PMC article. Review.
The Identification of CELSR3 and Other Potential Cell Surface Targets in Neuroendocrine Prostate Cancer.
Van Emmenis L, Ku SY, Gayvert K, Branch JR, Brady NJ, Basu S, Russell M, Cyrta J, Vosoughi A, Sailer V, Alnajar H, Dardenne E, Koumis E, Puca L, Robinson BD, Feldkamp MD, Winkis A, Majewski N, Rupnow B, Gottardis MM, Elemento O, Rubin MA, Beltran H, Rickman DS. Van Emmenis L, et al. Among authors: puca l. Cancer Res Commun. 2023 Aug 3;3(8):1447-1459. doi: 10.1158/2767-9764.CRC-22-0491. eCollection 2023 Aug. Cancer Res Commun. 2023. PMID: 37546702 Free PMC article.
Molecularly Targeted Therapies for Gastric Cancer. State of the Art.
Reddavid R, Dagatti S, Franco C, Puca L, Tomatis M, Corso S, Giordano S, Degiuli M. Reddavid R, et al. Among authors: puca l. Cancers (Basel). 2021 Aug 14;13(16):4094. doi: 10.3390/cancers13164094. Cancers (Basel). 2021. PMID: 34439248 Free PMC article. Review.
30 results